Skip to main content

Comparative Effects of Boric Acid and Calcium Fructoborate on Breast Cancer Cells

Abstract

Recent studies suggested that boron has a chemo-preventive role in prostate cancer. In the present report, we investigated the effects of calcium fructoborate (CF) and boric acid (BA) on activation of the apoptotic pathway in MDA-MB-231 human breast cancer cells. Exposure to BA and CF inhibited the proliferation of breast cancer cells in a dose-dependent manner. Treatment with CF but not BA resulted in a decrease in p53 and bcl-2 protein levels. Furthermore, after the treatment with CF, augmentation of pro-caspase-3 protein expression, cytosolic cytochrome c level, and caspase-3 activity were observed, indicating apoptotic cell death induction. This was also demonstrated by terminal deoxynucleotidyl transferase-mediated 2′-deoxyuridine 5′-triphosphate nick-end-labeling assay. In conclusion, our data provide arguments to the fact that both BA and CF inhibited the growth of breast cancer cells, while only CF induced apoptosis. Additional studies will be needed to identify the underlying mechanism responsible for the observed cellular responses to these compounds and to determine if BA and CF may be further evaluated as chemotherapeutic agents for human cancer.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Nielsen FH, Mullen LM, Gallagher SK (1990) Effect of boron depletion and repletion on blood indicators of calcium status in humans fed a magnesium-low diet. J Trace Elem Exp Med 3:45–54

    CAS  Google Scholar 

  2. Nielsen FH, Gallagher SK, Johnson LK, Nielsen EJ (1992) Boron enhances and mimics some effects of estrogen therapy in postmenopausal women. J Trace Elem Exp Med 5:237–246

    CAS  Google Scholar 

  3. Naghii MR, Samman S (1997) The effect of boron supplementation on its urinary excretion and selected cardiovascular risk factors in healthy male subjects. Biol Trace Elem Res 56:273–286

    PubMed  Article  CAS  Google Scholar 

  4. Strittmatter P (1964) Reversible direct hydrogen transfer from reduced pyridine nucleotides to cytochrome b5 reductase. J Biol Chem 239:3043–3050

    PubMed  CAS  Google Scholar 

  5. Rajendran KG, Burnham BS, Sood CA (1994) Spielvogel BF, Shaw BR, Hall IH, Anti-inflammatory and anti-osteoporotic activities of base-boronated nucleosides and phosphate-boronated nucleotides in rodents. J Pharm Sci 83:1391–1395

    PubMed  Article  CAS  Google Scholar 

  6. Belver A, Donaire JP (1983) Partial purification of soluble lipoxygenase of sunflower cotyledons: action of boron on the enzyme and lipid constituents. Z Pflanzenphysiol 109:309–317

    CAS  Google Scholar 

  7. Spielberg SP, Butler JD, MacDermot K, Schulman JD (1979) Treatment of glutathione synthetase deficient fibroblasts by inhibiting gamma-glutamyl transpeptidase activity with serine and borate. Biochem Biophys Res Commun 89:504–511

    PubMed  CAS  Article  Google Scholar 

  8. Cui Y, Winton MI, Zhang ZF, Rainey C, Marshall J, De Kernion JB, Eckhert CD (2004) Dietary boron intake and prostate cancer risk. Oncol Rep 11:887–892

    PubMed  CAS  Google Scholar 

  9. Gallardo-Williams MT, Chapin RE, King PE, Moser GJ, Goldsworthy TL, Morrison JP Maronpot RR (2004) Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice. Toxicol Pathol 32:73–78

    PubMed  Article  CAS  Google Scholar 

  10. Reed J (1999) Dysregulation of apoptosis in cancer. J Clin Oncol 17:2941–2953

    PubMed  CAS  Google Scholar 

  11. Miljkovic D (2000) US patent 6,080,425 (issued June 27, 2000)

  12. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254

    PubMed  Article  CAS  Google Scholar 

  13. Lee YJ, Chen JC, Amoscato AA, Bennouna J, Spitz DR, Suntharalingam M, Rhee JG (2000) Protective role of Bcl2 in metabolic oxidative stress-induced cell death. J Cell Sci 114:677–684

    Google Scholar 

  14. Gross A, McDonnell JM, Korsmeyer SJ (1999) Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899–1911

    PubMed  Article  CAS  Google Scholar 

  15. Lacroix M, Toillon RA, Leclercq G (2006) p53 and breast cancer, an update. Endocr-Relat Cancer 13:293–325

    PubMed  Article  CAS  Google Scholar 

  16. Haupt S, Berger M, Goldberg Z, Haupt Y (2003) Apoptosis—the p53 network. J Cell Sci 116:4077–4085

    PubMed  Article  CAS  Google Scholar 

  17. Barranco WT, Eckhert CD (2004) Boric acid inhibits humane prostate cancer cell proliferation. Cancer Lett 216:21–29

    PubMed  Article  CAS  Google Scholar 

  18. Barranco WT, Eckhert CD (2006) Cellular changes in boric acid-treated DU-145 prostate cancer cells. Br J Cancer 94:884–890

    PubMed  Article  CAS  Google Scholar 

  19. Chen F, Chang D, Goh M, Klibanov SA, Ljungman M (2000) Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ 11:239–246

    PubMed  CAS  Google Scholar 

  20. Shirangi TR, Zaika A, Moll UM (2002) Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J 16(3):420–422

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Scorei.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Scorei, R., Ciubar, R., Ciofrangeanu, C.M. et al. Comparative Effects of Boric Acid and Calcium Fructoborate on Breast Cancer Cells. Biol Trace Elem Res 122, 197–205 (2008). https://doi.org/10.1007/s12011-007-8081-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12011-007-8081-8

Keywords

  • Boric acid (BA)
  • Calcium fructoborate (CF)
  • Breast cancer
  • Apoptosis
  • MDA-MB-231